Significant itch relief in AD patients 12+ years of age with hand and/or foot involvement

AD-HAFT (12+ YEARS)

≥4-POINT REDUCTION IN HAND AND/OR FOOT PEAK PRURITUS NRS AT WEEK 16
(secondary endpoint)^1-3

Percentage of patients achieving endpoint

• 100
•  
• 70
• 60
• 50
• 40
• 30
• 20
• 10
• 0

Weeks

• 0
• 2
• 4
• 6
• 8
• 10
• 12
• 14
• 16

52%

14%

DUPIXENT 200/300 mg Q2W (n=67) Placebo (n=66)

Definitive conclusions cannot be made for time points earlier than Week 16 as those data were not multiplicity controlled and P value was nominal.

All DUPIXENT-treated patients in AD-HAFT received DUPIXENT monotherapy for their hand and/or foot lesions³

• Dosing for DUPIXENT in this study was consistent with the approved dosage in the Prescribing Information^1,3